|
Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That has Been Removed During Surgery Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That has Been Removed During Surgery conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That has Been Removed During Surgery Clinical research trials and Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That has Been Removed During Surgery health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That has Been Removed During Surgery. Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That has Been Removed During Surgery Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That has Been Removed During Surgery clinical trial. Human subjects frequently get the finest healthcare available for their Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That has Been Removed During Surgery condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "V" Clinical Trials Conditions > Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That has Been Removed During Surgery  Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That has Been Removed During Surgery
Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That has Been Removed During Surgery
For Condition: adenocarcinoma of the colon,stage 3 colon cancer,stage 2 colon cancer
Status: Recruiting
Sponsor(s): Intracel ,
Synopsis: RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy combined with leucovorin and fluorouracil in treating patients who have undergone surgery to completely remove stage II or stage III colon cancer.
Details: OBJECTIVES: - Determine safety and immunogenicity of adjuvant autologous tumor cell vaccine in patients with completely resected stage II or III adenocarcinoma of the colon. OUTLINE: This is a multicenter study. Patients are stratified according to disease stage (II vs III). Beginning 28-35 days after total surgical resection, patients receive adjuvant autologous tumor cell vaccine intradermally once weekly for 3 vaccinations. The first 2 vaccinations also contain BCG. Patients with stage II disease receive a fourth vaccination 6 months after surgical resection. Beginning 10-17 days after the third vaccination, patients with stage III disease receive adjuvant leucovorin calcium IV and fluorouracil IV on days 1-5. Chemotherapy continues every 28-35 days for a total of 6 courses. These patients also receive a fourth vaccination 1 month after the completion of chemotherapy. Patients are followed at 90 days and 6 months. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 21 Years/85 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed stage II or III primary adenocarcinoma of the colon - Completely resected within the past 28-35 days, at which time tumor tissue is harvested for vaccine production - No residual or metastatic disease - No more than 1 malignant invasive primary colon cancer - No tumor originating in the rectum (i.e., inferior tumor margin must not be at or below the peritoneal reflection) - No perforated tumors PATIENT CHARACTERISTICS: Age: - 21 to 85 Performance status: - WHO 0-1 Life expectancy: - Not specified Hematopoietic: - WBC greater than 4,000/mm^3 - Platelet count greater than 100,000/mm^3 - Hemoglobin greater than 10.0 g/dL Hepatic: - Bilirubin normal - SGOT normal - Alkaline phosphatase normal - No severe hepatic disease that would preclude study Renal: - Creatinine less than 1.5 times upper limit of normal - No severe renal disease that would preclude study Cardiovascular: - No prosthetic cardiac valves - No recent vascular prosthesis - No postsurgical cardiovascular complication - No severe cardiovascular disease that would preclude study Pulmonary: - No postsurgical pulmonary complication Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No insulin-dependent diabetes mellitus - No severe systemic disease that would preclude study - No congenital or acquired immune deficiency disease - No history of chronic ulcerative colitis, Crohn's disease, Gardner's syndrome, or Turcot's syndrome - No ileus - No other prior malignancy except curatively treated squamous cell or basal cell skin cancer or carcinoma in situ of the cervix - No ongoing infection requiring systemic antibiotics - No severe postoperative complication that would preclude study - Carcinoembryonic antigen normal PRIOR CONCURRENT THERAPY: Biologic therapy: - No other concurrent investigational immunotherapy Chemotherapy: - No prior systemic chemotherapy - No other concurrent investigational chemotherapy Endocrine therapy: - No concurrent steroids Radiotherapy: - No prior radiotherapy - No concurrent investigational radiotherapy Surgery: - See Disease Characteristics - No concurrent investigational surgery Other: - At least 3 weeks since prior systemic antibiotic therapy of more than 5 days duration (excluding topical antibiotics or perioperative prophylactic antibiotics) - No concurrent cytotoxic immunosuppressive agents
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MichaelHanna Jr., Study Chair, Intracel
John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital *Recruiting*
Allentown, Pennsylvania, 18105-1556
United States
Recruiting Linda Lapos 610-402-0500
Inova Fairfax Hospital *Recruiting*
Fairfax, Virginia, 22031
United States
Recruiting Thomas Wright 703-560-7788
Additional Information:
Study ID Numbers: CDR0000068597; INTRACEL-ASI-2002
Study Start Date:
Record last reviewed: June 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00016133
Other Stage 2 Colon Cancer Studies:
1. Combination Chemotherapy in Treating Patients With Colon Cancer
2. ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer That Has Not Responded to Chemotherapy
3. NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer
4. Fluorouracil, Phenylbutyrate, Indomethacin, and Interferon Gamma in Treating Patients With Advanced Colorectal Cancer
5. Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Related Studies:
Other stage 2 colon cancer Clinical Trials
Other Virginia Clinical Trials
Other Fairfax Clinical Trials
Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That has Been Removed During Surgery
|
|
|
|
|
|
|
|
